Q4 2021 Silk Road Medical Inc Earnings Call
[music].
Yeah.
Good day, ladies and gentlemen, and welcome to the Silk Road Medical's 2021 and fourth quarter earnings at this time all participants are in a listen only mode. Later, we will conduct a question and answer session and instructions will follow at that time, if anyone should require assistance. During the conference. Please press Star then.
Are you touched on telephone as a reminder, this conference call is being recorded I would now like to turn the conference over to your host ERISA by Investor Relations. Thank you. Please go ahead.
Thank you and thank you all for joining today's call. Joining me are Erica Rogers, Chief Executive Officer, and Lucas Buchanan, Chief Financial Officer, and Chief operating officer itself around medical.
Earlier today Silk Road medical released financial results for the three and 12 months ended December 31 2021.
A copy of the press release is available on the company's website.
Before we begin I'd like to remind you that management will make statements. During this call that include forward looking statements within the meaning of federal Securities laws, which are made pursuant to the safe Harbor provisions of the private Securities Litigation Reform Act of 1095.
Any statements contained in this call that relate to expectations or predictions of future events results or performance are forward looking statements.
All forward looking statements, including without limitation that was relating to our operating trends and future financial performance the impact of COVID-19 on our business and prospect for recovery expense management expectations for hiring physician training and adoption growth in our organization and reimbursement market opportunity commercial and international.
Spansion regulatory approval and product development are based upon current estimates and various assumptions.
These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward looking statements.
Accordingly, you should not place undue reliance on these statements for a list and description.
Correction of the risks and uncertainties associated with our business. Please refer to the risk factors section of our quarterly report on Form 10-Q .
10-K filed with the Securities and Exchange Commission on November nine 2021.
This conference call contains time sensitive information and is accurate only as of the live broadcast today February 24, 2020 to silk road medical disclaims any intention or obligation except as required by law to update or revise any financial projections or forward looking statements, whether because of new information future events or otherwise.
With that I will turn the call over to Erica Rogers Chief Executive Officer.
Thank you Marisa good afternoon, and thank you all for joining us.
I'd like to start by acknowledging the meaningful impact our teams and physicians had in 2021 which.
We treated nearly 14000 patients and surpassed $100 million in total revenue, we drove measurable progress on regulatory and reimbursement fronts in anticipation and support of standard surgical risk label expansion in the U S and our plan to entry into Japan, and China, while further developing our long.
Term pipeline.
We did all of this despite the significant headwinds faced by the U S health care system.
Our end goal hasn't changed to establish T car as the standard of care and what is now a 1.2 billion dollar market in the United States alone.
Highlighting our top line growth I am pleased to announce that we achieved $101.5 million in full year 2021 revenue representing 35% year over year growth, we continued to take meaningful share from carotid endarterectomy, while becoming the number one company in the U S curve.
Rhonda stent market by a wide margin.
We are encouraged by this success and believe we have many years of sustainable strong growth ahead of us to reach full market penetration.
Reviewing our regulatory and clinical achievements early in the year, we submitted a PMA supplement for standard surgical risk label expansion of our on route stent laying the foundation to unlock a 50% expansion of our U S total addressable market.
At the vascular annual meeting in August of 'twenty, 'twenty, one and independent analysis was presented illustrating equivalent risk of perioperative stroke death, or am I, plus ipsilateral stroke in a head to head comparison of C. A versus T car with cranial nerve injury.
We risk significantly reduced with T car.
The study affirmed the benefits of T car in the standard surgical risk patient population building on our long standing clinical evidence base and generating significant positive enthusiasm and the physician community.
We continue to expect the FDA to complete its review process within the first half of this year.
On the international front, we filed our shown in applications with P. M D. A in Japan for both the on route Neuro protection system and the on route stent last year.
And we submitted N M P. A in China for the stent with the N P. S system already under review.
Preliminary commercial steps are underway in both countries and we look forward to providing more detail as these initiatives progress.
Of course, this year was not without challenges and I want to recognize the immense efforts of our team our physicians and their tireless staff for continuing to put patients first throughout the peaks and valleys of COVID-19.
After a gradual improvement over the first half of the year, the third and fourth quarters were impacted by first Delta then omicron.
<unk> exiting the year were characterized by hospital staffing shortages policies pausing elective procedures and limited bed capacity.
Challenges have persisted through mid February again with regional variability of nuance.
Pressuring hospital based procedure volumes, including T car.
That said, we have now begun to see early favorable signs of recovery through improving daily T car counts.
In areas, where procedures and restrictions have lifted and the spread of COVID-19 has slowed.
These dynamics in mind, we are initiating guidance of $126 million to $132 million in full year 2022 revenue.
Our approach to guidance takes into account the scale of our U S sales territories and hospital accounts, the increasing experience of our trained physicians and the power of our continuously growing clinical evidence base all supporting the strength of T cars fundamental value proposition.
At the same time, our approach considers the challenges regional variability and uncertainty associated with the current environment.
<unk> will provide greater detail regarding our financials and forecast shortly.
I would now like to turn to our 2022 strategy. Our single most important objective. This year is driving U S. T car adoption, we are laser focused on continuing to increase our penetration into the large and still untapped pool of carotid procedure volume.
Liam, which we estimate included 169000 procedures in 2021 of which 13900, where T cars, representing approximately 8% of the market.
We finished 2021 with a presence in nearly 1000 hospital accounts covering the majority of the carotid procedures in America.
Within this concentrated hospital base, we have a critical mass of over 2000 trained physicians.
<unk> by 58 active sales territories, setting us up to drive deeper penetration in the years ahead.
We plan to continue adding to our commercial team in 2022 with the goal of increasing the amount of time, our sales professionals spend with each trained physician to drive greater adoption.
Our experience and our data show that the more experience a physician has with T car and the more touch points he or she has with our team the greater the impact is on his or her adoption curve.
By Segmenting, our physician data into courthouse, and measuring physicians adoption curves from the quarter during which they were initially trained.
We see steady growing adoption in each quartile overtime.
Our goal is to continue to accelerate the adoption curve of each physician cohort.
Let me take you through a few examples currently we are working with our physicians to address the pipeline of carotid disease patients, who whose care has been deferred or delayed.
Job one is preventing every possible stroke by driving patients back into the health care system, we have seen firsthand the devastating effects of rationing care in this critical disease and the message of not waiting is one that our team has been actively sharing to a strong response among our.
Physicians and their patients.
Recently, a leading physician in New York worked with our team to disseminate referring physician and patient education materials. After three patients in their health system had devastating strokes, while awaiting their T car procedures, two of which had been differed multiple times due to COVID-19 procedure cancellations.
In Louisiana, our team is educating physicians in the emergency room, where patients often first present with a stroke from carotid origin, leading to direct referrals from the E. R. T car physicians.
These are just two examples of how we are turning over every stone to continue driving awareness.
In addition, this year more than ever before we are promoting the obvious patient benefits in satisfaction of this minimally invasive approach because we know that when given a balanced choice patients choose T car oversee a nearly every time.
For example, Delray Medical Center in Florida, where physicians have performed over 200 T car procedures routinely offers T car N C. A to patients with patients embracing T car, most often due to the option for a faster and easier recovery and a return to full and <unk>.
Active lives.
And 2022 and beyond we will measure our success with this simple metric of T cars share of all carotid intervention and we are excited to drive this therapy from 8% penetration to a future where the vast majority of patients are served with the minimally invasive standards in stroke prevention T.
Car.
Key to this strategy is a leveling the playing field against carotid endarterectomy and in 'twenty 'twenty. Two we look forward to expanded T car labeling and reimbursement coverage to include standard surgical risk patients.
This will allow all patients at risk for a devastating stroke from carotid artery stenosis to have the opportunity for a safe less invasive procedure.
As I mentioned earlier, we are on track for standard surgical risk label expansion within the first half of this year, our dialogue with the FDA remains productive and we are keeping CMS and the society of vascular surgery abreast of the progress.
Our sales force is incredibly enthusiastic about this opportunity and we continue to prepare for commercial launch and the pertinent potential initiation of a post approval study do collect prospective data in the standard surgical risk patient population.
As a reminder, this indication would increase our total addressable market by roughly 50%.
But as we've indicated in the past we do not expect an expanded label to be an immediate revenue driver.
Rather we expect the indication to firmly establish T car on a level playing field with see a for all patients.
Adding to the many powerful reasons for physicians to adopt and perform T car.
We believe we are most likely to recognize gradual layering effect to our growth.
Profile, beginning in 2023 and beyond.
For this year, our focus will be on the Medicare coverage process awareness and education in the referring and treating physician community initiation of a post approval study and the continued support of physicians, gaining their experience and confidence and T car across a variety of patient pre.
<unk>.
In addition to our label expansion efforts on the regulatory side, we remain hard at work developing new and improved products to extend our leadership in the T car category.
Over the next 12 to 24 months, our pipeline of products includes new stent sizes and configurations improvements to our newer protection system and a dedicated balloon catheter are purpose built for T car, we look forward to providing more detail as these initiatives progress.
Looking further ahead, we continue to see meaningful potential in additional growth drivers to expand our impact on the market.
In 2020 , one we made progress on our Knight one I D E feasibility study and invested in additional pipeline development initiatives.
Core to these efforts, we created an innovation team in Minnesota, and augmented our capabilities substantially our new innovation center has simulated operating room environments, which enable us to have routine robust physician involvement early in our product development processes as well as shorten.
Cycle time on product iterations, we firmly believe that trans carotid technologies hold the potential to solve difficult clinical problems in the treatment of complex neuro vascular and cardiac disorders and will become an important part of the treatment paradigm in the future.
To summarize we are making meaningful progress on our many endeavors to drive near term procedure growth and invest in long term opportunities.
I will now turn the call over to Lucas Buchanan, our Chief Financial Officer, and Chief operating Officer.
Thank you Erica revenue for the three months ended December 31, 2021 was $28 3 million, a 34% increase from $21 1 million in the same period of the prior year.
Growth was driven primarily by increased procedures per trained physician sequentially and year over year as well as an expanding base of hospital accounts trained physicians and active sales territories, partially offset by ongoing regional headwinds related to COVID-19.
The number of <unk> procedures in the fourth quarter was just shy of 3935% increase from the same period for the prior year.
Similar to the regional variability seen in our third quarter 2021 results, our fourth quarter performance across regions Fareed with a clear tie to Covid hospitalizations in any given region.
As an example in regions, where COVID-19 patients as a percentage of all patients were relatively high in Q4 versus Q3 procedures per physician were flat to down sequentially, whereas in regions showing lower COVID-19 patients as a percentage of all impatiens procedures per physician grew sequentially.
By an average of 7%.
Gross margin for the fourth quarter of 2021 was 74% compared to 75% in the fourth quarter of the prior year.
The decline was driven by initial costs associated with the startup and expansion of our manufacturing activities at our new facility in Minnesota.
We expect gross margins to be slightly lower for the full year 2022 as compared to 2021 as we bring on this important new capacity to support our long term growth.
Total operating expenses for the fourth quarter of 2021 were $35 $1 million, a 14% increase from $30 9 million in the fourth quarter of 2020.
R&D expenses for the fourth quarter of 2021 were $7 $5 million compared to $10 million in the fourth quarter of 2020.
The decrease was primarily driven by a reduction in clinical expenses as compared to the fourth quarter of 2020, partially offset by an increase in personnel and product development program costs.
Sales general and administrative expenses for the fourth quarter of 2021 were $27 $6 million compared to $20 9 million in the fourth quarter of 2020.
The increase was primarily attributable to continued expansion of our sales team and commercial efforts and general and other corporate costs.
We expect continued growth in operating expenses in 2022, as we invest further in our pipeline and our sales team.
Net loss for the fourth quarter was $14 $7 million or a loss of 42 per share as compared to a net loss of $16 8 million or a loss of 49 per share for the same period of the prior year.
We ended 2021 with $110 $2 million of cash and cash equivalents.
Turning to our 2022 outlook and commercial strategy, we remain focused on driving the adoption curve and our significant trained physician base as well as preparing for a potential standard surgical risk indication.
We ended 2021 with a commercial presence and 975 hospitals and just shy of 2100 trained physicians served by 58 active sales territories.
And we expect to end 2022, with 70% to 75 active sales territories.
While driving adoption and our trained physician base is our primary focus we also expect to train 200 to 300, new physicians in 2022 and.
And we expect our physician base to perform over 17500 procedures for the year.
As Eric mentioned, we expect full year revenue to be in the range of $126 million to $132 million.
Representing growth of 27% at the midpoint over 2021 revenue of $101 5 million.
This includes an expectation for our first quarter revenues to be sequentially slightly lower than our fourth quarter 2021 revenues considering ongoing omicron related pressures.
That said, we are encouraged by gradually improving daily T car case counts and we remain optimistic that we will see recovery continue into March and the second quarter.
As always our guidance philosophy consider several variables, including a gradually improving health care operating environment as well as the potential for ongoing regional variability as Eric had mentioned in her earlier commentary.
Most importantly, our physician engagement remains high which is a testament to the established value of T car and an improving procedure outlook with the lifting of COVID-19 related restrictions and constraints.
At this point I would like to turn the call back to Erica for closing comments.
Thank you Lucas.
Looking back we introduced T car into the U S market just over a handful of years ago.
And today, leading physicians around the country considered T car as first line therapy and incredible achievement for a brand new category and paradigm shifting procedure.
<unk> is now available in nearly every hospital in the country treating meaningful quantities of carotid disease and over 40000 patients have been treated as of today.
We have built the infrastructure to move from ushering in to executing on T car as the new standard of care in minimally invasive treatment of carotid artery disease, we have the pieces the focus and the scale to move to double digit market penetration. This.
Year and make a difference in the lives of tens of thousands of additional patients and their loved ones. We have concretely established an entirely new market with a robust untapped opportunity ahead, and we have entered the next era of trans carotid therapies.
We will now open the line up to questions operator.
Thank you ma'am, ladies and gentlemen, if you have a question at this time. Please press. The Star then the number one key on your Touchtone telephone answer. Your question has been answered or you wish to remove yourself from the queue. Please press the pound key.
Your first question comes from the line of Joanne Wuensch from Citibank. Your line is open.
Okay.
Hi can you hear me okay.
Hi, Joanne.
How are you.
Good.
Excellent.
That was a lot.
Thank you for that.
You know what's interesting to me is how much.
Or how many physicians you plan on training over the coming year and I'd be curious to see what you're seeing in terms of procedural utilization or maybe the lack of a better term for those that have been trained in the last year or a person side without retrained, maybe pre pandemic or two years ago.
Sure well, let me take some of that and Lucas, we'll take some of that so so first and foremost we've said before and we can't we are committed to training as a part of this company probably for many years to come and so we view training physicians is a sort of an and to driving <unk>.
<unk> adoption, not an or and so it's critical that we continue to fill the pipeline of newly trained physicians and of course as we've talked about also.
Training Fellows, graduating vascular fellows remains an important part also of our training paradigm and so we intend to train roughly 200 or 300, new physicians in 2022.
And we ended up training about 644 physicians in in sort of what we would consider pandemic times and so job. One is getting those 660 644 physicians up and through that early part of their adoption curve gain.
Their comfort level with the procedure.
Excellent if I can get a follow up and when do you think your two targeted O U S.
Countries, Japan, and China start to contribute revenue.
I'll take that Joanne since we're still in the regulatory process and that will be followed by a reimbursement process in some market preparation activities thats not included in the guidance we've given this year.
Yeah.
Okay. Thank you very much I'll get back in queue.
Thanks Joanne.
Your next question is from Adam meter from Piper Sandler Your line is open.
Hi, everyone. The system run on for Adam and Thank you for taking the question.
I guess I just wanted to start off with.
Your latest trends on asymptomatic and symptomatic volumes I'm curious to know where that is today and how you think about that going forward.
Absolutely high summer and good to have you. So it's an interesting question because.
For most of normal times, the asymptomatic patient population is really the majority of the kinds of patients that get treated.
Representing about 70% typically of our procedural volume and why is that well, it's because it ideally you want to get at treating those ticking time bomb before it goes off and creates a stroke. We did see in periods in this pandemic fluctuations in that mix that sort of 70 30 mix and.
When elective procedures were put on hold we would sometimes see an increase on a percentage basis of symptomatic patients being treated.
But by and large as the pandemic wanes in terms of hospitalizations. We go back to our typical 70 30 split with asymptomatic representing about 70%.
Okay perfect. Thank you and then as we think about utilization trends in our models for 2022 can you help us think or provide a bit more color on what's embedded in the guidance there.
Sure I'm happy to take that so as we said our guidance relative to new physicians trained as two to 300.
And we trained roughly 290 in 2021, so that that brings us up to the just shy of 2100 as of the end of last year. So.
So if we just take the midpoint of that two to 300 for 2022.
B roughly 2000.
$302 50, or just shy.
So if you also triangulate that against our revenue guidance and kind of.
In excess of 17500 procedures.
That's kind of.
The combination of things that gets us to the the modeling aspects of your questions.
Got it thank you.
And I'll just add that the revenue per procedure. If you haven't done the math based on our full year results.
It was roughly 7300 that will probably come down a little bit in the future for reasons, we've addressed in the past, but that's that's the math.
Yes.
Your next question is from Robbie Marcus from Jpmorgan. Your line is open.
Oh, great. Thanks for taking the questions.
Just a quick clarification I feel like on the third quarter call. The timing for standard risk was by second quarter and I heard by the end of second quarter now did I Miss here on the third quarter call or did it move back a little bit.
I think you misheard on the on the second quarter call Robbie it's always been by the end of the second quarter. Okay.
So that's an easy one.
The second question as we think about standard risk, maybe just walk us through why it's going to be in your view a gradual.
A ramp in revenue I would imagine with the 50%.
Greater Tam.
No real difference in training at all it's the same procedure same docs.
What we would hold it back from being a rapid adoption.
[laughter], Yeah, I like the question Robby and good to have you by the way.
So look our expectations remain consistent which is you know hearing back from the FDA and hopeful label expansion in the first half of this year and following that is some effort with CMS as we've talked about before to obtain the coverage, we don't expect that to be protracted, but none of.
Less there's there's time involved and then we launch into an awareness and an education phase to make sure that all of our physicians understand that T. Car can then be indicated for the standard surgical risk patient.
And also educating referring physicians. This is an important piece of that as well and we'll sort of start up that engine on what we presume will be a post market post approval study in the standard surgical risk patient population, so theres a lot of activity there but.
But I think it's safe to say that that's not going to create an immediate spike what's important here is leveling the playing field and changing the way that we talk about T car in the context of all carotid patients and so over time I think we're going to see a gradual layer.
Ring, which is going to lead to.
Or ultimately, becoming the standard of care in our belief.
Got it.
Thank you and maybe just sneak a quick one in Lucas how do we think about expense growth in 2022 with all of the.
Launch activity and post approval study going on.
Sure. So we touched on the sales head count growing from 58.
Territories at the end of last year with a couple additional reps and training.
To ending this year roughly 70 to 75, so there's there's increased investment in the sales team head count.
As well there are a number of R&D initiatives, including the one you just just mentioned the potential initiation of a post approval study.
If we're able to get the standard surgical risk label expansion by the end of Q2 that will that will start up all of those activities in the second half of this year.
And we continue to invest in both.
Products and regulatory international regulatory processes for T car as well as for other trans carotid therapies as Eric had mentioned.
With our new pipeline and innovation team.
Infrastructure, and Minnesota complemented by our team in California, So theres a lot of exciting things going on to invest in on the R&D side, both for kind of short mid and long term growth drivers.
Yes.
Great. Thanks, a lot.
Your next question is from Rick Wise from Stifel. Your line is open.
Hi, Erika Hi, Luca this is actually John on for Rick Congrats on the quarter, you mentioned that one of your main priorities for 2022 is increasing penetration in T car adoption I just wanted to drill into that a little more could you tell me what exactly you think needs to happen to get there is it just continue to execute on.
<unk> principals or do you need to add more salespeople or have them alter kind of where their priorities are so any color there would be helpful.
Absolutely John Thanks, very much for joining us and please send our regards to rec and so you know one one think way to think about this is sort of the infrastructure that we've been building all along which is to get to what we consider a critical mass and its critical mass in the sales territories ending the year with 58 had a.
Heading to 70 or 75.
Nearly a thousand hospitals that account for the majority of carotid disease, well over 2000 physicians trained and a sizeable cohort of those physicians already having surpassed their kind of early adoption curve or getting to that 10, plus procedure, mark where they really gain.
And their confidence and so this is becoming a critical mass story versus a drilling down in the procedures per physician per quarter kind of metric.
That said I think I'm going to ask Luca to give a little more color on how we've been looking at procedures per physician to understand what we're doing is working to drive physicians up the adoption curve.
We've touched in the past on our kind of top quartile analysis.
In measuring physicians, regardless of what calendar year. They were trained kind of what their adoption curve looks like from that first quarter of training.
And that top quartile and top top half if you combine the top one or two core tiles continue to show really strong growth over time time and experience is our friend.
And.
Collectively the top half is doing.
Three to four procedures per quarter as you move out and we said in the past the <unk>.
Top half of that group is in Florida, and five to six range.
So we have.
And that that translates on a full year basis to still a lot of a lot of headroom to go in terms of further penetration rate we're nowhere near.
Maxed out there and then and then there's a lot in the bottom half of newly trained physicians and physicians trained in a pandemic in earlier.
Earlier on in there and their time and so we have tools and programs and tactics to focus on all those different quartile and segments and behavior attributes as we've talked about in the past one simple thing. We're doing is just expanding the sales team, which which by definition narrows the geography, because we're already in most of the hospitals we want it.
And we're just trying to narrow the size of these territories. So that we increase the touch points.
And we know that physicians time and experience with the procedure plus the higher energy of applying our tools and tactics and programs through our sales force.
Has a direct effect on the adoption curve. So some of this falls in the kind of good old fashioned commercial execution category.
So that we can we can achieve our growth profile.
Thanks, that's helpful and just one more for me you mentioned, the innovation team and getting that started up and potentially even shorter than product development cycles could you kind of on one hand quantify that for me and then just get into a little of what your expectations are for this team and have you seen any positive there so far.
Yes, absolutely. So we have not only been expanding our capabilities right here in our Sunnyvale headquarters in California in R&D.
But we took advantage of this new build out in Minnesota to put in a kind of stimulated operating room environment and physician.
Training center, so what that allows us to do is bring physicians in and have real hands on experience with our devices as they are iterating putting versions of these new devices in the hands of physicians early in these simulated environments. So that we can get immediate and real.
<unk> feedback, which shortens the cycle time of iteration, it's really that simple.
Not only that but gives us an opportunity to reinforce the benefits of T car and helped to drive adoption at the same time.
So in terms of the immediate impacts we talked about some products coming down the pipeline.
Which we will ultimately reveal more details on but we have really put a focus on making T car easier and even more simple for physicians and one example of that is this bespoke balloon, which will be designed for use in CCAR procedures, which were making very good progress on.
And Furthermore, changes to the neuro protection system.
While although working extraordinarily well and it's hard to imagine that you could improve upon it there are some things that we're doing based on physician feedback and we're turning those changes quite swiftly and then of course, there's the long term growth potential and those are really the fascinating and interesting.
<unk> products that are trans carotid and nature and address really complex clinical problems in both neuro and cardiac.
Thanks for taking my questions.
Thank you.
Your next question is from Daniel <unk> from SVP Leerink. Your line is open.
Good afternoon, everyone. Thanks, so much for taking that question Eric.
Eric I was curious about the fact that there's a potential incremental market expansion opportunity here and that it feels like over the last decade or so in the asymptomatic patient population carotid interventions have had it theres been a higher bar to intervene.
I think you know I don't know the exact number you might know, but maybe it varies by center, but is there an opportunity now with T car to move that bar back lower and intervene earlier in these asymptomatic patients. If so what what do you think it's going to take as the standard risk approvals on off or is it going to be more real world data.
Any thoughts there and then just one follow up for Luca.
Sure Hi, Danielle thanks, very much for joining us well firstly the good news is the.
The procedural volume has gone up moderately we reported 169000 is roughly the treated patient population now in the United States, which is an increase just in the treated patient population and and.
Your question is really about all of those patients who are diagnosed with critical carotid stenosis, but for whom they're they're not being treated and your point's a good one we've seen this and every other open to Endovascular conversion story that has gone before us in coronary or peripheral or neuro, where there is.
A market expansion effect and that is really driven by.
Demonstrating a reduction in the the morbidity and the mortality associated with the index procedure and so it's a combination of all of the things that you mentioned, it's a continue continued accumulation of the strong evidence base that we've already built more accumulation in patients who are considered at standard.
<unk> risk.
Which have potentially fewer morbidity comorbidities and continuing to drive awareness among referring physicians, but for sure. We know that when the only tool in the toolbox is a big invasive procedure.
That procedure is used extraordinarily conservatively.
And so while we're not turning our attention there just yet as we March through this very large untapped opportunity in the treated population eventually we will turn our attention to expanding this market.
And Daniel if I might just quickly there's a lot of discussion in the medical community about the downstream cardiovascular effects post COVID-19 infection.
As well as the deferral of routine health care that allowed chronic conditions like carotid artery disease to become more progressive.
And so we may be headed.
Into an era, where there is just more kind of screening and diagnosis of cardiovascular disease writ large.
Which which could filter to carotid artery disease, as well and as Erica mentioned just to put a finer point. The 169000 procedures is an update.
For 2021, that's relative to 166000, which was in our investor deck in 2019.
And arguably <unk> 2021 was a real COVID-19 impacted year and so one could ask the question should there have been even more diagnoses and procedures. So we like the the overall kind of demographic trends in this market.
Got it okay. Thank you for that and then Lucas question for you. The last few years have been.
Here's a heavy investment here and I appreciate the commentary on 2022 looking forward at what point can we start to really see you guys generate positive operating leverage.
And grow expenses at a significantly slower rate. Thanks, so much.
Well, we're seeing it right now our investments in new territories are quite productive.
Very quickly.
And so again when you've got the coverage model you need in terms of the number of hospitals in the number of sales territories to cover the treating physicians.
You can then drive operating leverage going from 8% penetration to something much bigger and so so so that is the key to our operating leverage we're going to we're going to start to see it even though we're still building out the sales team in 2022, we are seeing it and we'll see it.
More as a function of our penetration in the years ahead against that kind of fixed installed base in that critical mass we talk a lot about.
And that will give us fuel to drive our path to profitability, while investing in the R&D line along the way.
Thank you so much.
I am showing no further questions at this time I would now like to turn the conference back to Erica Rogers.
Thank you very much all of you for joining us at what is a very interesting time, we appreciate your time and attention. Thank you.
Yeah.
Ladies and gentlemen. This concludes today's conference. Thank you for your participation have a wonderful day you may all disconnect.
[music].
Yes.
Yes.
[music].
Yes.
[music].